Cell Therapeutics (CTIC) finishes the day up nearly 15% after saying earlier this morning that it's expecting the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) to release its opinion on the company's Marketing Authorization Application for Pixuvri in mid-February.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs